About Janaxa Pharmaceuticals Private Limited
Data last updated: 13 February 2026
Janaxa Pharmaceuticals Private Limited is a private limited company based in Chandigarh, Chandigarh, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 07 June 2012, the company has been in operation for over 14 years.
Registered with ROC Chandigarh under CIN U24232CH2012PTC033849.
Capital: an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. Formerly known as Lab Corp India Private Limited. It is led by directors Manoj Kumar and Rahul Khosla.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Sco 501 First & Second Floor Motor Market Manimajra, Chandigarh, Chandigarh, India – 160101.
As per the financials filed for FY 2025, the company reported a revenue of ₹2.6 Cr, a growth of 10% compared to the previous year.
The company is associated with 1 brand - Labcorp India. As per MCA filings, the company has open charges of ₹95 Lakh and satisfied charges of ₹19.5 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website labcorpindia.in.
-
Email*****@*****.com
-
Telephone**************
-
Website
-
Social Media**************
-
Registered AddressSco 501 First & Second Floor Motor Market Manimajra, Chandigarh, Chandigarh, India – 160101
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Janaxa Pharmaceuticals Private Limited
Janaxa Pharmaceuticals Private Limited operates one associated brand: Labcorp India. These brands represent Janaxa Pharmaceuticals Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Serves as a distributor of a diverse range of pharmaceutical drugs. | labcorpindia.org |
Competitors & Alternatives of Janaxa Pharmaceuticals Private Limited
Brands and companies operating in the same space as Janaxa Pharmaceuticals Private Limited include Entero Healthcare, AmerisourceBergen, Keimed and 3 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Entero Healthcare
|
India's leading healthcare products distribution platform | Mumbai, India, India | 2018 |
AmerisourceBergen
|
Pharmaceutical distribution and supply chain services are provided globally. | Chesterbrook, United States, United States | 1985 |
Keimed
|
Temperature-sensitive medicines are distributed via cold chain logistics by Keimed. | Hyderabad, India, India | 2000 |
Sandor Medicaids
|
Provider of medical equipment, devices, and drugs distribution services | Hyderabad, India, India | 1995 |
Dipna Pharmachem
|
Distributor of pharmaceutical raw materials | Ahmedabad, India, India | 2011 |
Mahaveer Medi Sales
|
Serves as a distributor of a wide range of pharmaceutical drugs. | Bengaluru, India, India | 2016 |
Business Activity of Janaxa Pharmaceuticals Private Limited
Janaxa Pharmaceuticals Private Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Janaxa Pharmaceuticals Private Limited
Janaxa Pharmaceuticals Private Limited is audited by VIKAS SANJIV & ASSOCIATES for the financial year 2022. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| VIKAS SANJIV & ASSOCIATES | blur-value | blur-value | blur-value |
Board of Directors of Janaxa Pharmaceuticals Private Limited
Janaxa Pharmaceuticals Private Limited is currently managed by 2 directors, with 4 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manoj Kumar | Director | 13 Jan 2014 | 12 Years 5 Months | Current |
|
Rahul Khosla
Also directs:
Plenum Biotech Private Limited
|
Director | 07 Jun 2012 | 14 Years 1 Months | Current |
Financials of Janaxa Pharmaceuticals Private Limited FY 2025 filings available
Janaxa Pharmaceuticals Private Limited reported revenue of ₹2.6 Cr (up 10% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Janaxa Pharmaceuticals Private Limited
As of FY 2022, Janaxa Pharmaceuticals Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Janaxa Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Jan 2024 | Hdfc Bank Limited | ₹60 Lakh | Open |
| 11 Jan 2022 | Hdfc Bank Limited | ₹35 Lakh | Open |
| 06 Oct 2021 | Others | ₹10 Lakh | Satisfied |
| 03 May 2019 | Others | ₹9.5 Lakh | Satisfied |
Total charge records: 4 View all charges
Employees and EPFO Compliance at Janaxa Pharmaceuticals Private Limited
View historical data on people associated with Janaxa Pharmaceuticals Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Janaxa Pharmaceuticals Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Janaxa Pharmaceuticals Private Limited
GSTIN & GST Filing Data of Janaxa Pharmaceuticals Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Janaxa Pharmaceuticals Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Janaxa Pharmaceuticals Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Janaxa Pharmaceuticals Private Limited
MSME Payment Delays by Janaxa Pharmaceuticals Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Janaxa Pharmaceuticals Private Limited
Subsidiaries & Group Companies of Janaxa Pharmaceuticals Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Janaxa Pharmaceuticals Private Limited with ownership details.
MCA Filings & Documents of Janaxa Pharmaceuticals Private Limited
MCA Filings & Documents of Janaxa Pharmaceuticals Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Janaxa Pharmaceuticals Private Limited
Frequently Asked Questions about Janaxa Pharmaceuticals Private Limited
Janaxa Pharmaceuticals Private Limited is an active private limited company in the pharma sector based in Chandigarh, Chandigarh, India. It was incorporated on 07 June 2012 (14+ years old) and is registered under CIN U24232CH2012PTC033849.
Janaxa Pharmaceuticals Private Limited reported revenue of ₹2.6 Cr for FY 2025 (up 10.00% YoY).
The current directors of Janaxa Pharmaceuticals Private Limited are:
The primary industry of Janaxa Pharmaceuticals Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Janaxa Pharmaceuticals Private Limited can be reached at the registered office: Sco 501 First & Second Floor Motor Market Manimajra, Chandigarh, Chandigarh, India – 160101, or through the website labcorpindia.in.
The authorised capital is ₹10 Lakh, and the paid-up capital is ₹10 Lakh.